Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Agnosia 1

Interventions

enzalutamide 16Magnetic Resonance Spectroscopy 16apalutamide 15Prednisone 12Androgen Antagonists 12Abiraterone Acetate 12Specimen Handling 11darolutamide 7abiraterone 7Radiotherapy 7Pluvicto 6Nivolumab 6Docetaxel 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6cabazitaxel 5Radiosurgery 5Lutetium-177 5Biopsy 5radium Ra 223 dichloride 4cabozantinib 4bicalutamide 4atezolizumab 4Standard of Care 4Lutetium 4olaparib 3gallium 68 PSMA-11 3Watchful Waiting 3Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Fulvestrant 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Ketorolac × 30 days × Clear all
NCT05597878 2026-06-01

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences

Phase 2/3 Terminated
58 enrolled
Genitourinary

Agnosia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡